BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu Y, Lai Y, Weng H, Tan L, Li Y, Chen G, Luo X, Ye Y. MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway. Aging (Albany NY) 2019;11:2551-64. [PMID: 31056532 DOI: 10.18632/aging.101876] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Yin Y, Li J, Rong J, Zhang B, Wang X, Han H. Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer. Immunopharmacol Immunotoxicol 2022;:1-14. [PMID: 35179434 DOI: 10.1080/08923973.2022.2038193] [Reference Citation Analysis]
2 Dong ZB, Wu HM, He YC, Huang ZT, Weng YH, Li H, Liang C, Yu WM, Chen W. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1. Cell Death Dis 2022;13:35. [PMID: 35013144 DOI: 10.1038/s41419-021-04491-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Li PH, Wang LQ, He JY, Zhu XL, Huang W, Wang SW, Qin QW, Sun HY. MicroRNA-124 Promotes Singapore Grouper Iridovirus Replication and Negatively Regulates Innate Immune Response. Front Immunol 2021;12:767813. [PMID: 34858424 DOI: 10.3389/fimmu.2021.767813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dashti F, Mirazimi SMA, Rabiei N, Fathazam R, Rabiei N, Piroozmand H, Vosough M, Rahimian N, Hamblin MR, Mirzaei H. The role of non-coding RNAs in chemotherapy for gastrointestinal cancers. Mol Ther Nucleic Acids 2021;26:892-926. [PMID: 34760336 DOI: 10.1016/j.omtn.2021.10.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
5 Zhao J, Wang Y, Su H, Su L. Non-coding RNAs as biomarkers for hepatocellular carcinoma-A systematic review. Clin Res Hepatol Gastroenterol 2021;45:101736. [PMID: 34146723 DOI: 10.1016/j.clinre.2021.101736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Liu F, Qian Y. The role of CD133 in hepatocellular carcinoma. Cancer Biol Ther 2021;22:291-300. [PMID: 33899676 DOI: 10.1080/15384047.2021.1916381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Mirzaei S, Hushmandi K, Zabolian A, Saleki H, Torabi SMR, Ranjbar A, SeyedSaleh S, Sharifzadeh SO, Khan H, Ashrafizadeh M, Zarrabi A, Ahn KS. Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies. Molecules 2021;26:2382. [PMID: 33921908 DOI: 10.3390/molecules26082382] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
8 Ghafouri-Fard S, Abak A, Mohaqiq M, Shoorei H, Taheri M. Interaction between non-coding RNAs and JNK in human disorders. Biomed Pharmacother 2021;138:111497. [PMID: 33735819 DOI: 10.1016/j.biopha.2021.111497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ghafouri-Fard S, Honarmand Tamizkar K, Hussen BM, Taheri M. MicroRNA signature in liver cancer. Pathol Res Pract 2021;219:153369. [PMID: 33626406 DOI: 10.1016/j.prp.2021.153369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
10 Zhang H, Yang X, Xu Y, Li H. KCNQ1OT1 regulates the retinoblastoma cell proliferation, migration and SIRT1/JNK signaling pathway by targeting miR-124/SP1 axis. Biosci Rep 2021;41:BSR20201626. [PMID: 33345272 DOI: 10.1042/BSR20201626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Taheri M, Shoorei H, Tondro Anamag F, Ghafouri-Fard S, Dinger ME. LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin. Exp Mol Pathol 2021;:104602. [PMID: 33422487 DOI: 10.1016/j.yexmp.2021.104602] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
12 Zhou L, Zhang Z, Huang Z, Nice E, Zou B, Huang C. Revisiting cancer hallmarks: insights from the interplay between oxidative stress and non-coding RNAs. Mol Biomed 2020;1:4. [PMID: 35006436 DOI: 10.1186/s43556-020-00004-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ye J, Sun D, Yu Y, Yu J. Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway. Aging (Albany NY) 2020;12:14406-17. [PMID: 32673286 DOI: 10.18632/aging.103484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]